drugset / Trial / NCT06640413
A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The aim of this study is to assess the safety of \[177Lu\]Lu-OncoFAP-23 alone or in combination with L19-IL2 for the treatment of advanced/metastatic Fibroblast Activation Protein (FAP)-positive solid tumors and to establish a Recommended Dose (RD).
Timeline
- Start
- 2025-10-31
- Primary completion
- 2028-05-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darleukin | Protein / enzyme biologic | 2.25e+07 iu | — |
| Subject | [177Lu]Lu-OncoFAP-23 | Other / unclassified | 3700 mbq | — |
| Subject | [177Lu]Lu-OncoFAP-23 | Other / unclassified | 7400 mbq | — |
| Subject | [177Lu]Lu-OncoFAP-23 | Other / unclassified | 11100 mbq | — |
Indications
No indication recorded.